SMMT

Summit Therapeutics
$13.11
−$0.55 (−4.06%)Jul 27, 2026
0.9PoorMoatMint rating

MoatMint rates Summit Therapeutics (SMMT) 0.9 out of 10, a research rating of the company's quality, value, growth, momentum and financial health. Its quality rating is 0.3 out of 10.

Key metrics

The numbers that frame SMMT today
Market cap
$10.45B
P/E (TTM)
-12.2
EV / FCF
-21.9
ROIC
-296.2%
Div yield
0%
Debt / equity
0.0
52wk Low
$12.55
52wk High
$30.98

SMMT stock rating

How SMMT scores on quality, value, growth, momentum and financial health
0.9out of 10
Low overallNeutral business, expensive priceTop 91% of ~5,000 US stocks
QualityPoor0.3/10
GrowthNeutral4.9/10
MomentumFair2.0/10
ValueFair2.7/10
Financial HealthFair2.8/10

Growth

Revenue and earnings trend for SMMT
RevenueNet income
See the full growth breakdown

Revenue and earnings trends, margins and the multi-year trajectory - free with an account.

Create a free account
Free foreverNo card required
Already a member? Log in

Cash flow & returns

Free cash flow and financial health
Free cash flowNet debt
See the full cash-flow picture

Free cash flow detail, returns on capital and the balance-sheet trend - free with an account.

Create a free account
Free foreverNo card required
Already a member? Log in

Insider trading

Recent insider buying and selling activity
PurchasesSales
Unlock every insider trade

See who is buying and selling, how much, and when - updated as new filings land.

Create a free account
Free foreverNo card required
Already a member? Log in

Frequently asked questions

Plain-English answers about SMMT
Is Summit Therapeutics a good buy?
No. Summit Therapeutics has poor quality and poor momentum. Both signals point to a weaker setup. Growth looks mixed. The support signal is useful, but not decisive. We think Summit Therapeutics is selling at a high price.
What is the market capitalization of SMMT?
Summit Therapeutics's market capitalization is $10.45B.
What is the P/E ratio for SMMT stock?
Summit Therapeutics's current P/E ratio is -12.2.
What is the 52-week high for SMMT stock?
The 52-week high for Summit Therapeutics is $30.98. The current close of $13.11 is 57.7% below that high.
What is the 52-week low for SMMT stock?
The 52-week low for Summit Therapeutics is $12.55. The current close of $13.11 is 4.4% above that low.
Does SMMT stock pay dividends?
Summit Therapeutics does not currently show a dividend per share in the company data.
What is the Debt / Equity ratio for SMMT?
Summit Therapeutics's Debt / Equity ratio is 0.03.